Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | DRAM Pricing · Big Tech Demand · Earnings Upgrades / 2026-01-19 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ROE Expansion · Net Cash · Shareholder Returns / 2026-07-29 Research
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | Sequential Segment Recovery · Order Pipeline Visibility · Form Factor Diversification / 2026-04-29 Research
  • [IR] SK hynix (000660 / SKHY) – Q2 2026 Earnings Presentation / 2026-07-29 IR Room
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Capacity Cannibalization · 1-Year LTA · Pricing Power / 2026-07-06 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Earnings Visibility · Shareholder Returns / 2026-08-03 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | North American ESS · European LFP Orders · Market Share Expansion / 2026-08-13 Research

[Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · HBM Market Share · Earnings Growth / 2026-07-01

Posted on July 1, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Kyobo Securities

Analyst : Choi Bo-young

Investment Rating : BUY (Maintained)

Target Price : KRW 4,000,000 (Upgraded)

Core Momentum : Expanding agentic AI adoption is expected to broaden DRAM and NAND demand amid structural supply deficits, while dominant HBM3e and HBM4 market positions strengthen the high-value product mix and sustain earnings growth.

📊 1. [Valuation & Key Financial Metrics]

  • Current Price (06/30): KRW 2,650,000 / Face Value: KRW 5,000
  • 52-Week High / Low: KRW 2,919,000 / KRW 245,000
  • KOSPI (06/30): 8,476.48p / KOSDAQ (06/30): 916.18p
  • Capital Stock: KRW 365.77 billion / Market Capitalization: KRW 1,888,661.3 billion
  • Common Stock Shares: 730.49 million / Foreign Ownership: 50.36%
  • Major Shareholders: SK Square and 8 others (20.50%)
  • 2026 Earnings Outlook: Revenue of KRW 35,805.1 billion (YoY +268.6%), Operating Profit of KRW 27,917.7 billion (YoY +461.0%, OPM 78.0%)
  • 2027 Earnings Outlook: Revenue of KRW 49,529.1 billion, Operating Profit of KRW 38,272.9 billion
  • PER (26.12E): 7.8x / PBR (26.12E): 5.2x / ROE (26.12E): 100.7%

🚀 2. [Market Opportunities & Business Outlook]

  • For 2Q26, revenue is projected at KRW 83.5 trillion (YoY +275.7%, QoQ +58.8%) and operating profit at KRW 63.5 trillion (YoY +589.0%, QoQ +68.8%, OPM 76.0%), meeting consensus forecasts, supported by wider-than-expected memory price increases and the weak Korean won.
  • [DRAM] B/G +8%, ASP +36%, Operating Profit of KRW 51.3 trillion (OPM 83.0%), [NAND] B/G +13%, ASP +60%, Operating Profit of KRW 12.1 trillion (OPM 57.0%) indicate ongoing price increases across all products in 2Q26, with higher HBM revenue contribution providing advantages in pricing power and margin defense over general memory.
  • Spreading agentic AI adoption is broadening demand across DRAM and NAND with structural supply deficits persisting through 2028, leading to continued earnings improvement driven by steep price escalation momentum in the second half.
  • High-value product mix improvements driven by a near-monopoly in HBM3e and over 60% market share in HBM4, alongside multi-year long-term supply agreements (LTAs), ensure reduced earnings volatility and extended cycle visibility.
  • The scheduled ADR listing on July 10 provides an opportunity to expand the global investor base and re-rate valuation, while additional upward revisions to forecasts remain possible depending on the outcome of 2027 HBM price negotiations.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates SK hynix as a company fully capitalizing on structural supply shortages driven by the spread of agentic AI, and as a high-value semiconductor enterprise reinforcing its premium product mix based on a near-monopoly in HBM3e and an overwhelming market share exceeding 60% in HBM4. This perspective places greater emphasis on reducing earnings volatility and securing long-term cycle visibility through expanded multi-year LTAs, moving well beyond a traditional short-term industry cycle rebound.

To determine whether this investment thesis is actively unfolding, key monitoring items include tracking whether steep price momentum in the second half translates into actual earnings performance, and whether the expansion of high-value market share in HBM3e and HBM4 directly enhances profitability. In addition, it is necessary to verify whether the expansion of multi-year LTAs leads to minimized earnings volatility and long-term visibility, alongside monitoring the realization of global investor base expansion and valuation re-rating following the scheduled ADR listing on July 10. These developments can be tracked through quarterly and annual earnings releases, official corporate IR materials, and regulatory filings on DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] Samsung Biologics (207940) – Shinhan Securities | Wage Negotiation Factors · Rockville Ramp-up · Plant 6 Catalyst / 2026-07-01
Next Post: [Research] Hanwha Ocean (042660) – Yuanta | Merchant Mix Improvement · CPSP Project Value · MASGA Catalysts / 2026-07-06

Related Posts

  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [Research] Alteogen (196170) – Hana Securities | Target Price Adjusted on Royalty Structure & Deal Assumptions · Deal Acceleration Starts in 2026 / 2026-01-22 Research
  • [Research] Celltrion (068270) – iM Securities | New Product Mix Expansion · First-Mover Advantage · Two-Track Long-Term Strategy / 2026-07-28 Research
  • [Research] Samsung SDI (006400) – iM Securities | ESS Business Pivot · AMPC Benefits · Earnings Visibility / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Hyundai Motor | Agentic AI · Memory Demand · Cycle Stability / 2026-05-13 Research
  • [Research] LIG D&A (079550) – iM Securities | Premier Air Defense Scarcity · Target Price Upgrade · Global Inquiries / 2026-05-08 Research
  • [Research] Samsung SDI (006400) – Hana Securities | Plant Utilization Recovery · North America ESS Demand · Valuation Re-rating / 2026-04-29 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2nd-Gen Biosimilar Penetration · COGS Ratio Stabilization · Global Capacity Expansion / 2026-05-07 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q2 2024 Earnings Presentation / 2024-07-31 IR Room
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · HBM4 · Valuation Appeal / 2026-07-30 Research
  • [Research] Hanwha Ocean (042660) – Daishin | Early Offshore Revenue · Naval Defense Pipeline · Excessive Discount / 2026-07-09 Research
  • [Research] ABL Bio (298380) – Shinhan Securities | Sanofi Strategy · Clinical Differentiation · Platform Expansion / 2026-02-02 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2023 Earnings Presentation / 2024-01-31 IR Room
  • [Research] Samsung SDI (006400) – Kiwoom Securities | Near-Term Sluggishness but Intact Momentum · 4Q26 Turnaround · Solid-State Pipeline / 2026-02-03 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme